Instrument Inactif

Communiqués NovaBay Pharmaceuticals, Inc. NYSE

Actions

US66987P1021

Blockchain & Cryptomonnaies

Cours en clôture NYSE
- ^USD	-

30/07	Stablecoin Development Corporation publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
17/07	Stablecoin Development Corporation annonce la nomination de Henry Blynn au poste de directeur de l'exploitation, à compter du 15 juillet 2026	CI

Communiqués

23/03	NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update	AQ
21/10/25	NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards	GL
18/09/25	NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting	GL
21/08/25	Investor Alert: NBY, OP, STAI, PNPNF - Stocks Under $1 Complete Watch List Inside	AQ
19/08/25	NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar	GL
10/03/25	NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders	AQ
07/03/25	NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders	BU
23/01/25	NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal	BU
19/12/24	NovaBay Pharmaceuticals : Announces the Further Adjournment of the Special Meeting of Stockholders Form 8 K	PU
19/12/24	NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders	BU
09/12/24	NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting	BU
22/11/24	NovaBay Pharmaceuticals : to Reconvene Special Meeting of Stockholders on December 18, 2024 Form 8 K	PU
22/11/24	NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024	BU
18/11/24	Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand	AQ
15/11/24	Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand	BU
07/11/24	NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results	BU
06/11/24	NovaBay Pharmaceuticals : Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price Form 8 K	PU
06/11/24	NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price	BU
29/10/24	NovaBay Pharmaceuticals : Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC Form 8 K	PU
29/10/24	NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC	BU
23/09/24	Acumen Health Holdings ('Acumen') to Acquire the Avenova brand from NovaBay Pharmaceuticals	AQ
23/09/24	NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets	AQ
20/09/24	NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets	BU
13/08/24	NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results	BU
01/08/24	NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024	BU